Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 10/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | USP1 | O94782 | 3/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3845542 | 0.89 | ADORA3 (0.38) | DDR1BRD4USP1 | |
| SCHEMBL3850528 | 0.86 | USP1 (0.36) | DDR1USP1 | |
| SCHEMBL3848468 | 0.81 | MCHR1 (0.42) | DDR1SLC6A4BRD4ADRA2AMCHR1 | |
| SCHEMBL3848466 | 0.81 | MCHR1 (0.42) | DDR1SLC6A4BRD4ADRA2AMCHR1 | |
| SCHEMBL13620497 | 0.79 | MCHR1 (0.45) | DDR1SLC6A4ADRA2AMCHR1NPY5R | |
| SCHEMBL13620287 | 0.76 | MCHR1 (0.42) | DDR1ADRA2AMCHR1NPY5R | |
| SCHEMBL13845184 | 0.76 | DDR1 (0.45) | DDR1BRD4ADRA2AMCHR1USP1 | |
| SCHEMBL3845187 | 0.75 | ADORA3 (0.37) | SLC6A4USP1 | |
| SCHEMBL3845141 | 0.75 | USP1 (0.40) | USP1 | |
| SCHEMBL13620258 | 0.74 | MCHR1 (0.46) | DDR1ADRA2AMCHR1USP1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009062059-A2 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | DDR1 3201/4885SLC6A4 4574/4885BRD4 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.